Navigation Links
Warren Lammert Joins IntelliMedix Board of Advisors
Date:2/27/2013

ATLANTA, Feb. 27, 2013 /PRNewswire-iReach/ -- IntelliMedix announced that Warren Lammert has been appointed to its Board. Lammert is the Chairman and co-founder of the Epilepsy Therapy Project and Epilepsy.com and is also a board member for FACES (Finding a Cure for Epilepsy and Seizures) at New York University.

"Warren brings an impressive track record accelerating innovation for new therapies in the field of epilepsy.  Warren's drive, passion and proven business acumen will be a great contribution to the Intellimedix team.  Warren will help us achieve our goal of finding cures for Dravet Syndrome, epilepsy and other neurological disorders. We are fortunate and excited to have him on board," said Daniel Fischer , President and CEO of Intellimedix.

Mr. Lammert is Founder, Principal and Chief Investment Officer of Granite Point Capital and has more than 18 years of investment industry experience. Prior to the formation of Granite Point Capital, he spent 14 years at Janus serving in several investment and senior management roles, including most recently, Portfolio Manager of the Janus Mercury Fund from its inception in 1993 until March 2003.

"I am thrilled to join with Intellimedix in working to build new approaches to drug discovery for Dravet Syndrome and other orphan and human diseases.  Jim Jacoby and Daniel Fischer have assembled a team with a remarkable breadth of expertise but what impresses me most is the range of effective collaborative partnerships that the Intellimedix team has built and nurtured around key emerging discovery technologies," said Warren Lammert .

Also sitting on the Board is Jim Jacoby , Chairman of the Board for IntelliMedix and CEO of Jacoby Development.

About IntelliMedix:

IntelliMedix was founded in early 2012 with the purpose of developing and applying novel technologies to accelerate the discovery of new therapies for neurological diseases and creating new approaches for personalized medicine. They employ cutting-edge technology that includes gene sequencing, in silico screening, optogenetics, synthetic biology, and high-throughput in vivo and in vitro models. The company's current focus is on developing new treatments for specific types of intractable epilepsy (e.g., Dravet Syndrome) and other neurological disorders. For more information, please visit http://www.intellimedix.com

Media Contact:

Joanna Morrison Intellimedix, 770-399-9930, jmorrison@intellimedix.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE IntelliMedix
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. FASEB joins President Obama in urging Congress to sustain investments in research and innovation
2. Book shows evolution that joins human and environmental sciences
3. Brazil joins global initiative for biodiversity data access
4. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
5. Brazil joins international marine research effort
6. Steve Fisher joins American Health IT LLC as VP of Operations
7. Hass Avocado Board study published in Food & Function journal
8. Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
9. JoVE establishes Librarian Advisory Board
10. Diving board sensors key to DNA detection
11. Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic (IVD) ... mergers and acquisitions (M&A), and Kalorama Information expects that ... acquisitions have been shifting. Generally, uncertainty in reimbursement and ... the U.S. has changed the acquisitions landscape. Instead of ... in companies buying partners outside of their home country ...
(Date:1/13/2017)... Jan. 13, 2017 Sandata Technologies, LLC, ... the homecare industry, including Electronic Visit Verification™ (EVV™), ... Justin Jugs, as Senior Vice President of Product ... years of homecare experience to Sandata, where he ... plans to align Sandata,s suite of solutions with ...
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... BILLERICA, Mass. , Jan. 24, 2017 ... acquired Hysitron, Inc., a technology leader in ... test instrumentation. The acquisition adds Hysitron,s innovative ... of atomic force microscopes (AFMs), surface profilometers, ... enhancing Bruker,s leadership position in nanomaterials research ...
(Date:1/24/2017)... Jan. 24, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... have agreed to increase the size of the offering by ... Company, together with warrants to purchase 1,842,106 shares of common ... per share of common stock (the "Exercise Price"), at a ... warrant (the "Public Price"). The warrants have a term of ...
(Date:1/24/2017)... ... January 24, 2017 , ... Men who ... leptin levels had a positive association with increased prostate growth or benign prostatic ... International Neurourology Journal involved 571 Korean men who underwent urological examinations, including ...
(Date:1/24/2017)... Switerland (PRWEB) , ... January 24, 2017 , ... ... first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine ... which are available in a range of concentrations from six different malaria strains, ...
Breaking Biology Technology: